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Background: MicroRNAs are endogenous non-coding RNAs that play important roles in a wide variety of biological
processes such as apoptosis, development, aging and cancer. The aberrant expression of miRNAs may contribute to
phenotypic features of malignant cells, including resistance to chemotherapy. However, in cholangiocarcinoma
(CCA) the correlation between miRNAs and their potential roles in CCA remains unclear.
Methods: MicroRNA profiles were analyzed in three pairs of CCA tumor specimens and non-tumorous-paired biliary
tissues using Agilent microRNA microarrays. Expression of selected miRNAs was further confirmed in CCA tissues
and CCA cell lines by q-PCR. The effects of miR-144 were evaluated by cell proliferation, migration, transwell, and
tumorigenicity assays. Expression of LIS1 (platelet-activating factor acetylhydrolase isoform 1b) was assessed in CCA
specimens and CCA cell lines by q-PCR and western blot. Targeting of LIS1 by miR-144 was confirmed by luciferase
reporter assays.
Results: We found that the expression of 28 miRNAs in CCA tissues was significantly different from their corresponding
adjacent normal bile duct tissues. We focused on miR-144 which was significantly down-regulated in CCA tissues.
Reintroduction of miR-144 in CCA cell lines not only inhibited cell growth, but also significantly reduced cell migration
and invasion capacities compared with controls. Luciferase assays and western blots verified LIS1 as a direct target of
miR-144, and knocking-down LIS1 has similar effect with overexpression of miR-144 in CCA cell lines. Moreover,
overexpression of miR-144 expression could suppress tumor growth in nude mice.
Conclusions: Our results showed that miR-144 was reduced in CCA tissues and suggested that miR-144 may be
an essential suppresser of CCA cell proliferation and invasion through targeting LIS1.
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Cholangiocarcinoma (CCA) is a malignant tumor of bile
duct epithelial cells, and the incidence and prevalence of
CCA have been increasing worldwide over recent decades
[1,2]. The survival rate of patients with CCA is very poor
with a median survival of 6–12 months, as it is most often
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unless otherwise stated.lymph node metastases [3-5]. Despite advances in surgical
techniques, systemic chemotherapy and/or radiotherapy,
radical surgery remains the only curative treatment for
this devastating disease [6-10]. Therefore, an improved
understanding of the molecular mechanisms of tumor
initiation, progression, and metastasis formation of CCA
is urgently required as the basis to identify novel thera-
peutic targets and develop effective therapeutic strategies.
MicroRNAs (miRNAs) are endogenous, single-stranded,
non-coding, small RNAs that regulate gene expression by
preferentially binding to specific sequences in the 3′-un-
translated region (3′-UTR) of their target mRNAs [11].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of miRNAs contributes to a variety of biological processes
including embryonic development and tumorigenesis
[12-15]. Several studies have demonstrated significant
changes of miRNA expression levels in CCA tissue in
comparison with paired noncancerous bile duct. Further-
more, deregulated miRNAs have been identified that act
as oncogenes or tumor suppressors [16-22]. These results
suggest that miRNAs can contribute to tumor growth,
although the possible molecular mechanisms remain to be
further elucidated.
In the present study, we first performed a comprehen-
sive analysis of miRNA expression profiles in CCA tissues
and paired noncancerous bile ducts. We found that miR-
144 was significantly down-regulated in CCA tissues and
CCA cell lines. To investigate the role of miR-144 in can-
cer cells, we examined the cellular effects of miR-144
overexpression. We also identified LIS1 as a novel target
gene of miR-144. Furthermore, LIS1 silencing could imi-
tate the phenomenon of miR-144 overexpression. These
results provide insight into the molecular mechanisms of




A total of 70 paired human CCA samples with histo-
logical evidence were obtained from the Department of
Biliary-Pancreatic Surgery, Affiliated Tongji Hospital
(Hubei, China). Tumor tissues and the corresponding
adjacent normal tissues were frozen in liquid nitrogen
and stored at −80°C until use. Written informed con-
sent was obtained from all patients and the study was
approved by the Institutional Review Boards of the Affili-
ated Tongji Hospital of Huazhong University of Science
and Technology.
MiRNA microarrays and miRNA target prediction
Total RNA was extracted from three CCA tissues and
matched adjacent, non-tumor bile duct tissues using
TRIZOL (Invitrogen, Carlsbad, CA, USA) according to
the supplier’s instructions. The miRNA expression pro-
file was determined using the Agilent Human miRNA
Microarray Kit (V2) (Agilent Inc., Santa Clara, CA,
USA) (Sanger database v.12.0). Hybridized microarray
slides were scanned with the Agilent Scanner G2565A
and Agilent Feature Extraction version 9.5 was used to
extract signals. Data analyses including Gene Ontology
analysis, Pathway Analysis, and MicroRNA-gene network
were performed (shbiochip, Shanghai, China). The target
genes of miR-144 were obtained from public databases
(miRanda, PicTar, and Target ScanS) according to the
following two criteria: the target gene contained the
conserved 8-mer and 7-mer sites that match the seedregion of miR-144, and the target gene was predicted by
at least two programs.Cell culture and transient transfection
Human embryonic kidney HEK293T cells were obtained
from American Type Culture Collection, and human CCA
cell lines (HCCC-9810, CCLP1, HuCC-T1, and RBE) were
conserved by our laboratory.The nonmalignant cholangio-
cyte cell line BECwere generously provided by Hiromi
Ishibashi, Japan.All cells were maintained in DMEM or
RPMI 1640 supplemented with 10% v/v fetal bovine
serum (FBS) (Gibco, Grand Island, NY, USA), 100 U/mL
penicillin, and 100 μg/mL streptomycin at 37°C in a hu-
midified incubator containing 5% CO2.
For transfection, HuCC-T1 and RBE cells were
transfected with anti-miR-144 inhibitors (anti-miR-
144) or Anti-miRNA Inhibitors Negative Control #1
(NC) (Applied Biosystems, Foster City, CA, USA) in a
final concentration of 20 nM using X-tremeGENEsiRNA
Transfection Reagent (Roche, Indianapolis, IN, USA), ac-
cording to the manufacturer’s instructions. The expression
levels of miR-144 were quantified 24 h after transfection,
and the cells were examined by western blot analysis 48 h
after transfection. HCCC-9810 and CCLP1 cells were
transfected with specific chemosynthesized siRNA se-
quences for targeting human LIS1 (gene ID: 5048) or
NC. The sequences of siRNA are supplied in Additional
file 1: Table S1. Silencing of LIS1 was confirmed by
western blot analysis 48 h after transfection.Plasmid constructs and lentiviral transduction
To generate the lentiviral vector pCDH-miR-144 that
overexpresses miR-144, a fragment encoding the pre-miR-
144 sequence was amplified by PCR from HEK293T
cell genomic DNA and then cloned into the BamHI/
EcoRI sites of the pCDH-CMV-EF1-copGFP vector
(SBI, Mountain View, CA, USA).
The sequences of the LIS1 3′-UTR containing putative
seed sequences of miR-144 were amplified from CCLP1
genomic DNA and cloned into the psiCHECK™-2 vector
(Promega, Madison, WI, USA). The cloned 3′-UTR of
LIS1 was mutated using Quickchange (Stratagene, San
Diego, CA, USA). The sequences of primer are supplied
in Additional file 1: Table S1. The successful sequences
and insertions were confirmed by DNA sequencing.
For production of viral particles, we co-transfected the
lentivirus-mediated miR-144 packaging system containing
pCDH-CMV-EF1-copGFP or PCDH-miR-144, Rec, TAT,
Gag, and Vsvg into HEK293T cells with Lipofectamine™
2000 (Invitrogen) according to the manufacturer’s in-
structions. The supernatant containing virus source was
collected 60 h post-transfection and filtered by a filter
with 0.45-μm pore size (Millipore).
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and then transfected with either pCDH-CMV-EF1-copGFP
(vector) or PCDH-miR-144 for 12 h. Stable cell lines were
screened by mass sorting on a FACSAria flow cytometer
(BD Biosciences, Mountain View, CA, USA) based on the
expression of GFP carried by the lentviral vector 72 h after
transfection.
RNA extraction and q-PCR
Total RNA was extracted from CCA cancer tissues or cells
using Trizol reagent (Invitrogen) following the manu-
facturer’s instruction. For miR-144 detection, TaqMan
miRNA expression assays were used to evaluate the
expression of miR-144 using the StepOnePlus™ system
(Applied Biosystems). To quantify the LIS1 mRNA
levels, 500 ng of total RNA was subjected to first-strand
cDNA synthesis using a PrimeScript RT Reagent kit
(Takara, Dalian, China) according to the manufacturer’s
instructions. q-PCR was performed with 2 × SYBR Green
PCR master mix (Takara) on the iQ5™ quantitative PCR
detection system (Bio-Rad, Richmond, CA, USA) and the
results were analyzed with IQ5 software. The primers used
in the reactions are listed in Additional file 1: Table S1. U6
and GAPDH were used as endogenous controls. All reac-
tions were run in triplicate and all experiments were run
in triplicate.
Cell proliferation assays
Logarithmic growth phase cells were seeded at a density
of 4 × 103 cells per well in a 96-well plate containing
0.1 ml RPMI 1640 medium and 10% FBS. Cell Counting
Kit-8 (CCK-8) (Dojindo, Tokyo, Japan) reagent was
added at 0, 24, 48, and 72 h after seeding and incubated
at 37°C for 2 h. The data of OD (optical density) value at
450 nm were measured by a microplate reader (Bio-Rad).
Each experiment was performed three times with five
replicates.
Cell migration and invasion assays
Migration and invasion activities of cells were evaluated
by wound healing and invasion assays. Cells were seeded
in 6-well plates and the confluent monolayer cells (at
80% confluence) were scratched with a sterile 100-μL
pipette tip. Images of the migrated cells were taken using
a digital camera (Leica, Heerburg, Germany) 48 h later.
The extent of wound healing was assessed by the distance
traversed by cells migrating into the denuded area. In the
invasion assay, the upper chamber of the transwell inserts
with 6.5-mm polycarbonate membranes with 8.0-μm
pores (Corning) was coated with Matrigel mixed with
serum-free medium (diluted at 1:5) (BD Biosciences). A
total of 5 × 104 cells were resuspended in serum-free
medium and placed in the upper chamber, while 600 μL
medium containing 20% FBS was placed in the lower well.After 48 h, cells that did not migrate or invade were re-
moved using a cotton swab. Invasive cells at the bottom of
the membrane were washed twice with PBS, fixed in 4%
paraformaldehyde, stained with 0.1% crystal violet, and
counted under an inverted microscope. All experiments
were performed in triplicate and were repeated three
times.
Luciferase reporter assay
HEK293T cells at 50% confluence in 96-well plates were
co-transfected with hsa-miR-144 or anti-miR-144, along
with reporter vectors using Lipofectamine™ 2000. The
firefly and Renilla luciferase activities were measured
48 h after transfection using the Dual-Luciferase Reporter
Assay System (Promega) on an illuminometer (Lumat LB
9507, Berthold, Germany). Renilla luciferase acted as a re-
porter gene and firefly luciferase as a normalized control
for each individual analysis.
Tumorigenicity assays in nude mice
The use of nude mice complied with the NIH Guide for
the Care and Use of Laboratory Animals and local insti-
tutional ethical guidelines, and the study was approved
by the Experimental Animal Ethics Committee of Tongji
Medical College of Huazhong University of Science and
Technology. Eight mice were used in each group. Four-
week-old female nude mice (BALB/c-nude) were injected
subcutaneously in the upper back with 5 × 106 CCLP1
cells stably transfected with empty vector or miR-144 vec-
tor in 150 μL sterile PBS. Tumor growth was measured
with calipers every 7 days and the tumor volumes were
calculated using the formula: 1/2 (length × width2). Mice
were sacrificed and tumor weight was examined 5 weeks
later.
Western blot
Cells were harvested with 1× cell lysis buffer (Promega).
A total of 60 μg of total proteins were separated on 10%
polyacrylamide gel and transferred to nitrocellulose mem-
branes (Bio-Rad). The membranes were blocked with 1%
bovine serum albumin in TBST buffer (Tris Buffer Saline
containing 0.1% Tween-20) for 1 h at room temperature,
and subsequently incubated with antibodies against LIS1
(PA5-20419, pierce), Akt (#4691, Cell Signaling Technol-
ogy), p-Akt (#4058, Cell Signaling Technology), MMP-2
(#4022, Cell Signaling Technology), or GAPDH (#2118,
Cell Signaling Technology) overnight at 4°C. After extensive
washing with TBST buffer, the blots were then incubated
with goat anti-rabbit, horseradish peroxidase-conjugated
secondary antibody for 1 h at room temperature. Protein
bands were detected by enhanced chemiluminescence
reagents ECL (Millipore, MA, USA) and the intensity of
the bands was analyzed using Image J software (National
Institute of Health, USA).
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Data were expressed as the mean ± standard deviation
(SD). Statistical analyses were performed with GraphPad
Prism 5.0 (GraphPad Software). miR-144 expression was
compared in CCA tissues and matched adjacent, non-
tumor bile duct tissues by the paired Student’s t test. The
relationship between miR-144 and LIS1 expression was
carried out by Spearman’s correlation. A P-value of <0.05
was regarded as statistically significant.
Results
The miR-144 is downregulated in CCA tissues and cell lines
As miRNAs have critical functions in the regulation of
many biological processes such as cell proliferation and
metastasis, we compared the miRNA expression profiles
between three pairs of CCA samples and the correspond-
ing normal bile duct tissues. Taking a twofold difference
as the cut-off point, microarray analysis detected 19 up-
regulated and 9 downregulated miRNAs in the three pairs
of CCA and corresponding non-tumor tissues (Figure 1A).
To study the possible role of miRNAs that inhibit CCA
cell proliferation and metastasis, we focused on miR-144,
as it is significantly downregulated in CCA samples. To
validate the expression of miR-144 in miRNA microarray
data, we confirmed that the expression of miR-144 was re-
markably reduced in the three CCA samples compared
with the corresponding normal bile duct tissues (data not
shown).Figure 1 Differential miRNA expression profiles in malignant bile duc
clustering was performed using log2 relative frequencies of 29 differentially
represents underexpressed miRNAs. B. Endogenous levels of miR-144 in HC
analysis. C. Relative expression of miR-144 in CCA tissues was significantly l
indicates CCA tissue samples, and non-tumor indicates adjacent normal bilNext, we compared the expression of miR-144 in a
panel of human CCA cell lines (HCCC-9810, CCLP1,
HuCCT1, and RBE) and the non-malignant cell line BEC,
and the results showed that miR-144 expression was sig-
nificantly decreased in these CCA cell lines (P <0.05)
(Figure 1B). Furthermore, we measured the expression
levels of miR-144 in the 70 pairs of human primary
CCA tumor and adjacent, normal bile duct tissue samples
and found that miR-144 was significantly downregulated
in CCA cancer tissues compared with adjacent non-
neoplastic tissues (P <0.01) (Figure 1C). These data indi-
cated that miR-144 was decreased in CCA cancer tissues
and cells, and thus it might be involved in human CCA
development.
MiR-144 suppresses cell proliferation, migration and
invasion in CCA cells
To investigate the effects of miR-144 in CCA cells,
HCCC-9810 and CCLP1 cells were transfected with either
vector or pCDH-miR-144. We confirmed that miR-144
was significantly increased in HCCC-9810 and CCLP1
cells after transfection with pCDH-miR-144 compared
with the vector by qPCR (P <0.01) (Figure 2A). Overex-
pression of miR-144significantly decreased cell prolifera-
tion compared with control cells expressing vector after
48 h and 72 h (P <0.05) (Figure 2B, C).
The vast majority of deaths from cancer are due to
tumor cells spreading from the primary tumor to otherts and adjacent normal bile ducts. A. Unsupervised hierarchical
expressed miRNAs. Red represents overexpressed miRNAs; green
CC-9810, CCLP1, HuCC-T1, RBE, and BEC cells detected by q-PCR
ower than that in corresponding normal bile duct tissues. Tumor
e ducts. U6 was used as a loading control. *P < 0.05, **P < 0.01.
Figure 2 (See legend on next page.)
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Figure 2 MiR-144 suppressed proliferation and invasion of cholangiocarcinoma cell lines through the AKT Pathway. A. Relative
miR-144 expression level in HCCC-9810 and CCLP1 cells transfected with the control (empty vector) or miR-144-expressing vector (miR-144).
B and C. Effects of stably expressing miR-144 on CCA cell proliferation were determined by cell proliferation assay. D. Representative images
of invasion assays. The bar graph showed quantification of cell invasion between the miR-144-transfected cells and the control cells. E.
Representative results of wound healing assays. F. Quantification of migrated cells with indicated treatment. G. Western blot analysis to
assess the protein levels of AKT, p-AKT, and MMP2 in HCCC-9810 and CCLP1 cells with miR-144 overexpression. GAPDH was used as an
internal control to normalize protein signal intensity. Data are shown as mean ± SD and were representative of three independent experiments.
*P <0.05, **P < 0.01.
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reintroducing miR-144 would decrease the invasive and
migration potential of CCA cells. Transwell assay was
performed to analyze the effect of miR-144 on the inva-
sive behavior of HCCC-9810 and CCLP1 cells. Overex-
pression of miR-144 reduced cell invasion abilities of the
CCA cells compared with the control cells (Figure 2D).
Quantitative analyses of the results indicated that migra-
tion of miR-144-overexpressed cells was decreased at
48 h compared with control cells (P <0.05) (Figure 2D).
Scratch assays showed that miR-144-overexpressed cells
retained a larger scratch area (P <0.05) (Figure 2E,F).
It is well known that the Akt signaling pathway is the
most important survival pathway that plays a central
role in diverse cellular functions, including proliferation
and metastasis and the phosphorylation of AKT atS473
is the best marker of activated AKT signaling pathway.
So after we saw the inhibition effect of miR-144 on CCA
cell proliferation, the first thing we thought about was to
detect the status of pAKT (S473). The data showed that
the level of p-AKT was significantly decreased in cells
overexpressing miR-144 compared with control cells
(Figure 2G). Moreover, it was reported that tumor cell
invasion is activated by MMP2, which is a 72 kDa type
IV collagenase involved in the breakdown of extracellu-
lar matrix to help cell invasion [23], and AKT signaling
pathway activates MMP2 and enhances cell invasion in
different cancers, such as breast cancer and lung cancer
[24,25]. As predicted, miR-144 overexpression reduced
the expression of the MMP2 which explained why the
cell incvasion activity decreased in both HCCC-9810
and CCLP1 cells (Figure 2G). These observations indicated
that miR-144 inhibits cell growth and invasion through
suppression of AKT signaling pathway.
LIS1 is a direct target of miR-144
There is no evidence that miR-144 suppresses AKT
activity directly. To explore the underlying mechanisms
by which miR-144 inhibits the proliferation and invasion
of CCA cells through suppression of AKT, the direct
target genes of miR-144 were obtained from public
databases. LIS1 was one of the predicted targets, and
we examined the 3′-UTR of LIS1 mRNA and identi-
fied two conserved putative miR-144 binding sites bycomputational algorithms (Figure 3A). To verify LIS1 as a
direct target of miR-144, we co-transfected HEK293T cells
with a LIS1 luciferase reporter vector which contains a
wild-type or mutated binding site for miR-144 together
with or without miR-144, followed by luciferase reporter
assay. To further examine the relative contribution of the
two candidate miR-144-binding sites, mutations of four
nucleotides in each seed-binding site (MUT1 and MUT2)
and a mutation of two binding sites (MUT) were included,
which abolish the putative miRNA-mRNA interactions
(Figure 3A). Our data indicated that miR-144 attenuated
the luciferase activity of the wild-type 3′-UTR of LIS1
(P <0.01) and reduced the luciferase activity of both the
individual binding site mutants (P <0.05) (Figure 3B),
but the activity of the double mutant 3′-UTR vector
remained unaffected. These results showed that both
putative miR-144-binding sites contribute to the regula-
tion of LIS1. In addition, overexpression of miR-144 re-
sulted in decreased endogenous mRNA and protein
levels of LIS1 in CCA cells compared with cells trans-
fected with the control vector (Figure 3C and D). On
the contrary, western analysis showed that LIS1 protein
expression was significantly increased in miR-144 inhibi-
tor transfected cells (Figure 3). Taken together, these re-
sults demonstrated that miR-144 inhibited the expression
of LIS1 through post-transcriptional repression.
LIS1 is a functional target of miR-144 and is inversely
correlated with miR-144 levels
To investigate the effects triggered by the targeting of
LIS1 by miR-144 in cultured CCA cells, we used small
interfering RNA (siRNA) knockdown of LIS1 to evaluate
effects in proliferation and invasion. Transfection of si-LIS1
resulted in efficient depletion of LIS1in both HCCC-9810
and CCLP1 cells compared with cells transfected with
negative control (NC) (Figure 4A). The levels of p-AKT,
and MMP-2 also decreased (Figure 4A). Cell proliferation
assays revealed that knockdown of LIS1 suppressed pro-
liferation of HCCC-9810 and CCLP1 cells (P <0.05)
(Figure 4B,C). In addition, LIS1 silencing reduced cap-
abilities of cell invasion both in HCCC-9810 and CCLP1
cells compared with control cells (P <0.05) (Figure 4D).
Prior evidence suggested that LIS1 was upregulated in
lung cancer patients and enhanced migration and invasion
Figure 3 LIS1 is a new target regulated by miR-144. A. Schematic of the two predicted seed regions in the 3′-UTR of LIS1 and
mutated 3′-UTR. B. Luciferase activity was assayed in HEK293T cells. The wild-type (WT) or mutated LIS1 3′-UTR reporter gene vector was
co-transfected with vector or miR-144 (MUT1 and MUT2: mutations of each binding site; MUT: mutation of both binding sites). All values
represent the mean of five independent experiments performed in duplicate. C. q-PCR analysis examined the mRNA level of LIS1 after
overexpression of miR-144 in HCCC-9810 and CCLP1 cells. D. Endogenous protein levels of LIS1 in HCCC-9810 and CCLP1 cells after
indicated treatments were detected by western blots. E. Western blot showed the expression of LIS1 in HuCTT1 and RBE cells transfected
with negative control oligonucleotide (NC) or miR-144 inhibitor (anti- miR-144). Data are shown as mean ± SD and were representative of
three independent experiments. *P <0.05, **P < 0.01.
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LIS1 in CCA patients, we examined the mRNA level of
LIS1 in the same patient cohort used for measuring miR-
144 levels and found an increased expression of LIS1
mRNA levels in tumors compared with normal controls
(P <0.01) (Figure 4E). Of interest, an inverse correlation
was observed between miR-144 and LIS1 in human CCA
tissues (Figure 4F). These results confirmed LIS1 as a
functional downstream target of miR-144.
MiR-144 attenuated the growth of CCA cells in a nude
mouse xenograft model
Our previous studies showed that miR-144 restoration
inhibited cell growth and invasiveness in vitro. There-
fore, we performed xenograft formation assays to
evaluate the effect of miR-144 overexpression on tumori-
genicity. Stable transfection of miR-144 in CCLP1 cells
delayed tumor formation and caused a dramatic reduc-
tion of tumor size compared with the control vector
(Figure 5A). Analysis of tumor weight revealed that
miR-144 overexpression markedly reduced tumor growth
after 5 weeks compared with vector tumors (P <0.01)
(Figure 5B). All these findings further indicated the
tumor suppressive effect of miR-144 on CCA both in vitro
and in vivo.Discussion
CCA is the most malignant neoplasm compared with
many other malignant tumors [3,4,7,8]. Although sur-
gical resection plus adjuvant chemotherapy results in
better outcome of early-stage patients, long-term survival
remains low. Accumulating evidence shows that expres-
sion levels of various miRNAs are downregulated in
cancer, indicating that these miRNAs may act as tumor
suppressors [27-29]. However, the roles of miRNA in
cell proliferation and invasion of CCA are not yet fully
clear. In this study, we used miRNA expression profiles
to identify 28 differentially expressed miRNAs. This
approach confirmed the differential expression of sev-
eral miRNAs such as miR-495 and miR-486, which are
involved in cancer cell growth and invasion in vitro and
in vivo [30,31].
Although the research on the true biological relevance
of miR-144 in cancer is still in its infancy, in this study,
we focused on the expression and function of miR-144
in CCA. MiR-144 has been implicated in both oncogenic
or tumor suppressor roles in different tumors [32-34],
but its role in CCA is not yet clarified. Here, we found
that miR-144 acts as a possible tumor suppressor in
CCA. First, our data show that miR-144 is significantly
downregulated in CCA tissues and cell lines. Furthermore,
Figure 4 Effects of siRNA-mediated knockdown of LIS1 on CCA cell proliferation, invasion, and migration. A. Western blot was used to
detect the expression of LIS1, AKT, p-AKT, and MMP2 in HCCC-9810 and CCLP1 cells transfected with indicated siRNAs (20 nmol/L) 48 h after
transfection. B and C. The cell proliferation curve of HCCC-9810 and CCLP1 cells transfected with LIS1 siRNA or control for 48 h. D. Representative
results of invasion assays. The bar graph showed quantification of cell invasion between cells transfected with LIS1 siRNA and control. E. The
mRNA levels of LIS1 were detected in CCA tumor tissues or matched adjacent tissue by q-PCR.GAPDH was used as a internal control. F. Expression
of miR-144 was inversely correlated with LIS1 in CCA tissues. Statistical analysis was performed using Pearson’s correlation coefficient. (R2 = 0.49,
P <0.01). *P < 0.05, **P <0.01.
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nificantly attenuate cell proliferation, migration, and
invasion in vitro. The inhibitory effect of miR-144 was
also confirmed in CCA cells in vivo.
To elucidate the mechanism of miR-144 inhibiting
cancer, first, we tested the AKT signaling pathway, which
is usually activated in cancer and increase cell growth.
We saw activity of AKT was decreased significantly by
overexpression of miR-144. Furthermore, MMP2, a col-
lagenase which promotes cell invasion and is activatedby AKT, was downregulated by miR-144. All these
showed that miR-144 inhibits CCA cell growth and inva-
sion through suppressing AKT. But we could not find
any direct regulation of AKT by miRNAs. Then we tried
to find the direct target of miR-144, which would explain
how miR-144 suppresse AKT. Platelet-activating factor
acetylhydrolase 1b, also named LIS1, was first identified
as a causative gene for type I lissencephaly disease. Here,
we predicted that LIS1 is a potential target of miR-144
based on the evolutionally conserved 3′-UTR sequence
Figure 5 miR-144 suppresses tumor growth in vivo. Representative tumor xenografts excised from SCID mice. Quantitation of tumor weight
in recipient mice at week 5 after indicated treatments. **P < 0.01.
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a direct target of miR-144. A previous study indicated
that LIS1 could organize the microtubule cytoskeleton
and regulate cell migration in Drosophila [35]. A recent
study reported that LIS1 overexpression promoted cancer
cell invasion and was significantly associated with poor
survival in lung adenocarcinoma [26]. Our results revealed
that the expression of LIS1 is remarkably increased in
CCA tissues, and knockdown of LIS1 by siRNA has simi-
lar inhibition effect on the growth and motility properties
of CCA cell lines with miR-144 overexpression. In another
word, even there is other direct target of miR-144, the
inhibition effect of miR-144 in CCA is mainly through
decreasing LIS1. However, some studies showed that
LIS1 was downregulated in hepatocellular carcinoma
and ectopic expression of LIS1 could significantly inhibit
hepatocellular carcinoma cell proliferation and colony for-
mation [36]. The discrepancy of LIS1 expression between
CCA and hepatocellular carcinoma might be due to
tissue-specific gene expression and functions. The de-
crease of p-AKT was also observed when knocking
down LIS1 by siRNA. It suggests that the regulation of
LIS1 by miR-144 is in the upstream of AKT and LIS1 may
be a upstream activator of AKT directly or undirectly.
This study presents that miR-144 is a tumor suppressor
in CCA through inhibition of AKT and also finds its direct
target LIS1, which is the major effector in the tumor sup-
pression process. Besides, a new direction is addressed by
this study that LIS1 could affect AKT signaling pathway.Conclusions
Here, we conducted miRNA expression profiling analysis
between the CCA tissues and paired bile ducts, followed
by experimental validation in CCA tissues and cell lines.
We found that miR-144 is down-regulated in CCA,
and our results suggest that miR-144 inhibits CCA cell
growth and invasion through decreasing p-AKT and
directly targeting LIS1. Thus, these studies not only
substantially broaden our understanding of the com-
plex mechanisms underlying the pathogenesis of CCAbut also implicate potential new interventional and
therapeutic strategies. However, future studies examin-
ing the correlation between miR-144 expression status
and clinic pathological parameters and elucidating the
precise signal transduction pathways of miR-144 are
warranted.
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